DNTH
Price
$18.49
Change
-$0.27 (-1.44%)
Updated
Aug 11, 01:05 PM (EDT)
Capitalization
603.85M
GERN
Price
$1.36
Change
+$0.08 (+6.25%)
Updated
Aug 11, 02:55 PM (EDT)
Capitalization
816.66M
87 days until earnings call
Interact to see
Advertisement

DNTH vs GERN

Header iconDNTH vs GERN Comparison
Open Charts DNTH vs GERNBanner chart's image
Dianthus Therapeutics
Price$18.49
Change-$0.27 (-1.44%)
Volume$300
Capitalization603.85M
Geron
Price$1.36
Change+$0.08 (+6.25%)
Volume$6.43K
Capitalization816.66M
DNTH vs GERN Comparison Chart in %
Loading...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNTH vs. GERN commentary
Aug 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a StrongBuy and GERN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 11, 2025
Stock price -- (DNTH: $18.76 vs. GERN: $1.28)
Brand notoriety: DNTH and GERN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 89% vs. GERN: 114%
Market capitalization -- DNTH: $603.85M vs. GERN: $816.66M
DNTH [@Biotechnology] is valued at $603.85M. GERN’s [@Biotechnology] market capitalization is $816.66M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 0 FA rating(s) are green whileGERN’s FA Score has 0 green FA rating(s).

  • DNTH’s FA Score: 0 green, 5 red.
  • GERN’s FA Score: 0 green, 5 red.
According to our system of comparison, DNTH is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 4 TA indicator(s) are bullish while GERN’s TA Score has 4 bullish TA indicator(s).

  • DNTH’s TA Score: 4 bullish, 5 bearish.
  • GERN’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DNTH is a better buy in the short-term than GERN.

Price Growth

DNTH (@Biotechnology) experienced а -8.89% price change this week, while GERN (@Biotechnology) price change was +9.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.37%. For the same industry, the average monthly price growth was +31.89%, and the average quarterly price growth was +19.43%.

Reported Earning Dates

GERN is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+22.37% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GERN($817M) has a higher market cap than DNTH($604M). DNTH YTD gains are higher at: -13.945 vs. GERN (-63.842). GERN (-114.49M) and DNTH (-116.76M) have comparable annual earnings (EBITDA) . GERN has more cash in the bank: 397M vs. DNTH (263M). DNTH has less debt than GERN: DNTH (1.4M) vs GERN (122M). GERN has higher revenues than DNTH: GERN (116M) vs DNTH (6.52M).
DNTHGERNDNTH / GERN
Capitalization604M817M74%
EBITDA-116.76M-114.49M102%
Gain YTD-13.945-63.84222%
P/E Ratio3.24N/A-
Revenue6.52M116M6%
Total Cash263M397M66%
Total Debt1.4M122M1%
FUNDAMENTALS RATINGS
DNTH vs GERN: Fundamental Ratings
DNTH
GERN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
57100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
8165
P/E GROWTH RATING
1..100
6776
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNTH's Valuation (54) in the null industry is somewhat better than the same rating for GERN (92) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than GERN’s over the last 12 months.

DNTH's Profit vs Risk Rating (57) in the null industry is somewhat better than the same rating for GERN (100) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than GERN’s over the last 12 months.

DNTH's SMR Rating (96) in the null industry is in the same range as GERN (97) in the Biotechnology industry. This means that DNTH’s stock grew similarly to GERN’s over the last 12 months.

GERN's Price Growth Rating (65) in the Biotechnology industry is in the same range as DNTH (81) in the null industry. This means that GERN’s stock grew similarly to DNTH’s over the last 12 months.

DNTH's P/E Growth Rating (67) in the null industry is in the same range as GERN (76) in the Biotechnology industry. This means that DNTH’s stock grew similarly to GERN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNTHGERN
RSI
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
85%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
87%
Momentum
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
85%
MACD
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
74%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
82%
Advances
ODDS (%)
Bullish Trend 22 days ago
79%
Bullish Trend 11 days ago
73%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 4 days ago
78%
Aroon
ODDS (%)
N/A
Bearish Trend 4 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DALVX20.590.14
+0.68%
Dunham Large Cap Value A
TRZKX75.610.24
+0.32%
T. Rowe Price International Discovery Z
BKLSX10.110.03
+0.30%
BlackRock U.S. Insights Long/Shrt Eq K
TIMVX18.150.02
+0.11%
Nuveen Mid Cap Value R6
MFCIX41.020.03
+0.07%
Meridian Contrarian Investor

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with IMNM. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
-2.04%
IMNM - DNTH
54%
Loosely correlated
-1.82%
XNCR - DNTH
51%
Loosely correlated
-1.23%
ERAS - DNTH
49%
Loosely correlated
-4.11%
CRNX - DNTH
49%
Loosely correlated
-3.69%
SYRE - DNTH
48%
Loosely correlated
N/A
More

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
-1.54%
SER - GERN
65%
Loosely correlated
+1.10%
SYRE - GERN
39%
Loosely correlated
N/A
UTHR - GERN
38%
Loosely correlated
+0.69%
DYN - GERN
35%
Loosely correlated
N/A
DNTH - GERN
35%
Loosely correlated
-2.04%
More